WO2012075414A3 - Aptamer bioconjugate drug delivery device - Google Patents

Aptamer bioconjugate drug delivery device Download PDF

Info

Publication number
WO2012075414A3
WO2012075414A3 PCT/US2011/063102 US2011063102W WO2012075414A3 WO 2012075414 A3 WO2012075414 A3 WO 2012075414A3 US 2011063102 W US2011063102 W US 2011063102W WO 2012075414 A3 WO2012075414 A3 WO 2012075414A3
Authority
WO
WIPO (PCT)
Prior art keywords
aptamer
delivery device
biopolymer
active agent
particles
Prior art date
Application number
PCT/US2011/063102
Other languages
French (fr)
Other versions
WO2012075414A2 (en
Inventor
Steven Bloembergen
Ian J. Mclennan
Nathan Jones
Ryan Wagner
Aareet Krsna Ganesh Shermon
Abdel Rahman Elsayed
Juewen Liu
Original Assignee
Ecosynthetix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2011336352A priority Critical patent/AU2011336352B2/en
Priority to JP2013542213A priority patent/JP6035633B2/en
Priority to US13/990,278 priority patent/US10285943B2/en
Priority to EP11845209.3A priority patent/EP2645991B1/en
Priority to CA2819240A priority patent/CA2819240C/en
Application filed by Ecosynthetix Ltd. filed Critical Ecosynthetix Ltd.
Publication of WO2012075414A2 publication Critical patent/WO2012075414A2/en
Publication of WO2012075414A3 publication Critical patent/WO2012075414A3/en
Priority to PCT/US2012/056582 priority patent/WO2013081720A1/en
Priority to US14/360,503 priority patent/US11369570B2/en
Priority to AU2012318273A priority patent/AU2012318273B2/en
Priority to US16/383,998 priority patent/US20190374469A1/en
Priority to US17/376,837 priority patent/US20210338585A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch is disclosed. The device may be in the form of an aptamer-biopolymer-active agent conjugat, where the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a high shear force in the presence of a crosslinker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked nydrogel particles in water. The biopolymer may be functionalized. The aptamer may be conjugated directly to the cross-linked biopolymers. The active agent may be a drug useful for the treatment of cancer. The delivery device survives for a period of time in the body sufficient to allow for the sustained release of a drug and for the transportation and uptake of the conjugate into targeted cells.
PCT/US2011/063102 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device WO2012075414A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2011336352A AU2011336352B2 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device
JP2013542213A JP6035633B2 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery system
US13/990,278 US10285943B2 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device
EP11845209.3A EP2645991B1 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device
CA2819240A CA2819240C (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device
PCT/US2012/056582 WO2013081720A1 (en) 2011-12-02 2012-09-21 Aptamer bioconjugate drug delivery device
AU2012318273A AU2012318273B2 (en) 2011-12-02 2012-09-21 Aptamer bioconjugate drug delivery device
US14/360,503 US11369570B2 (en) 2010-12-02 2012-09-21 Aptamer bioconjugate drug delivery device
US16/383,998 US20190374469A1 (en) 2010-12-02 2019-04-15 Aptamer bioconjugate drug delivery device
US17/376,837 US20210338585A1 (en) 2010-12-02 2021-07-15 Aptamer bioconjugate drug delivery device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41910610P 2010-12-02 2010-12-02
US61/419,106 2010-12-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/990,278 A-371-Of-International US10285943B2 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device
US16/383,998 Continuation US20190374469A1 (en) 2010-12-02 2019-04-15 Aptamer bioconjugate drug delivery device

Publications (2)

Publication Number Publication Date
WO2012075414A2 WO2012075414A2 (en) 2012-06-07
WO2012075414A3 true WO2012075414A3 (en) 2012-09-13

Family

ID=46162465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063102 WO2012075414A2 (en) 2010-12-02 2011-12-02 Aptamer bioconjugate drug delivery device

Country Status (6)

Country Link
US (6) US20120141551A1 (en)
EP (1) EP2645991B1 (en)
JP (1) JP6035633B2 (en)
AU (1) AU2011336352B2 (en)
CA (1) CA2819240C (en)
WO (1) WO2012075414A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075414A2 (en) * 2010-12-02 2012-06-07 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
US20120309246A1 (en) 2011-06-03 2012-12-06 Alexander Tseitlin Curable biopolymer nanoparticle latex binder for mineral, natural organic, or synthetic fiber products and non-woven mats
CA2880615A1 (en) * 2012-08-03 2014-02-06 Ecosynthetix Ltd. Bio-based binder and fiberglass insulation
WO2014078636A1 (en) * 2012-11-16 2014-05-22 President And Fellows Of Harvard College Nucleic acid hydrogel self-assembly
CA3036216A1 (en) * 2012-12-20 2014-06-26 Lantmannen As-Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
CN103467610B (en) * 2013-09-13 2016-06-08 青岛农业大学 A kind of method that ultrasonic wave added TEMPO prepares starch nanometer granule
WO2015084372A1 (en) 2013-12-05 2015-06-11 Ecosynthetix Ltd. Formaldehyde free binder and multi-component nanoparticle
KR20170003091A (en) * 2015-06-30 2017-01-09 주식회사 넥스모스 An Aptamer Functionalized Smart Hydrogel for Skin Pack, Wrap, Patch and Facial Mask and a method of preparing the same
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN113876600B (en) * 2015-10-21 2024-05-17 密歇根大学董事会 Detection and treatment of caries and microcavities with nanoparticles
WO2017093466A1 (en) 2015-12-02 2017-06-08 Gothenburg Sensor Devices Ab A method for determining a hydrodynamic size of an object
CA3052297A1 (en) * 2017-02-02 2018-08-09 Caris Science, Inc. Targeted oligonucleotides
WO2019079164A1 (en) * 2017-10-16 2019-04-25 University Of Cincinnati Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme
KR20200135963A (en) 2018-03-28 2020-12-04 그린마크 바이오메디컬 인코포레이티드 Phosphate crosslinked starch nanoparticles and dental treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20090196831A1 (en) * 2006-05-04 2009-08-06 Emory University Nanostructures, methods of synthesizing thereof, and methods of use thereof
US20100166872A1 (en) * 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2148951A (en) 1937-04-15 1939-02-28 Du Pont Organic starch derivatives and process
US2328537A (en) 1940-08-09 1943-09-07 American Maize Prod Co Thick-bodied starch and method of making
US2500950A (en) 1945-12-29 1950-03-21 Nat Starch Products Inc Ungelatinized starch ethers from polyfunctional etherifying agents
US2819240A (en) 1953-10-23 1958-01-07 Petrolite Corp Reaction products of carboxylated phenol-aldehyde resins and aminemodified phenol-aldehyde resins and process of making same
US2801242A (en) 1954-08-06 1957-07-30 Corn Prod Refining Co Process for the preparation of distarch phosphate and the resulting product
US2929811A (en) 1958-11-28 1960-03-22 Bernard T Hofreiter Starch products of stable viscosity
US2989521A (en) 1959-06-30 1961-06-20 Frederic R Senti Method of cross-linking and oxidizing starch
GB1420392A (en) 1973-06-29 1976-01-07 Scholten Honig Research Nv Aqueous starch adhesive
US4126669A (en) 1975-06-02 1978-11-21 Pharmacia Aktiebolag Diagnostic agent
DE3734491A1 (en) 1987-10-12 1989-04-20 Henkel Kgaa METHOD FOR PRODUCING A DRY PRODUCT SUITABLE AS A SMOKING BASE
ATE262006T1 (en) 1995-07-12 2004-04-15 Valtion Teknillinen THERMOPLASTIC STARCH AND METHOD FOR PRODUCING
NL1006444C2 (en) 1997-07-01 1999-01-05 Inst Voor Agrotech Onderzoek Encapsulation of active substances.
US6696089B2 (en) * 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
JP2002527408A (en) 1998-10-09 2002-08-27 ミシガン大学 Hydrogel and water-soluble polymer carrier for drug delivery
NL1010926C2 (en) 1998-12-30 2000-07-03 Inst Voor Agrotech Onderzoek Process for the preparation of starch particles.
WO2000069916A1 (en) 1999-01-25 2000-11-23 Ato B.V. Biopolymer nanoparticles
US6379494B1 (en) 1999-03-19 2002-04-30 Weyerhaeuser Company Method of making carboxylated cellulose fibers and products of the method
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
JP2004500438A (en) 2000-04-14 2004-01-08 アルニス　バイオサイエンシーズ，　インコーポレイテッド High-affinity peptide-containing nanoparticles
CA2406395A1 (en) 2000-04-14 2001-10-25 Alnis Biosciences, Inc. High affinity peptide-containing nanoparticles
EP1176255A1 (en) 2000-07-24 2002-01-30 The Dow Chemical Company Use of starch dispersions as binder in coating compositions and process for preparing the starch dispersions
US20040126900A1 (en) 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
DE60213080T2 (en) 2001-05-02 2007-01-11 Ecosynthetix Inc., Lansing ENVIRONMENTALLY FRIENDLY BIOPOLYMIC ADHESIVES AND SUITABLE APPLICATIONS
ES2266088T3 (en) 2001-05-02 2007-03-01 Ecosynthetix Inc. METHOD FOR THE PRODUCTION OF CORRUGATED CARTON AND PRODUCT OBTAINED WITH THE SAME.
GB0117767D0 (en) 2001-07-20 2001-09-12 Unilever Plc Polymers and their synthesis
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
EP1482956A1 (en) 2002-02-01 2004-12-08 Vanderbilt University Targeted drug delivery methods
EP1531868A2 (en) * 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
US20040247683A1 (en) 2003-05-02 2004-12-09 Carmen Popescu Biodegradable nanoparticles incorporating highly hydrophilic positively charged drugs
GB0310673D0 (en) 2003-05-09 2003-06-11 Givaudan Sa Alginate matrix particles
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
ES2311226T3 (en) 2004-05-05 2009-02-01 Firmenich Sa BIODEGRADABLE INTEGRATED COPOLYMERS.
CA2571899A1 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8043480B2 (en) 2004-11-10 2011-10-25 The Regents Of The University Of Michigan Methods for forming biodegradable nanocomponents with controlled shapes and sizes via electrified jetting
US8048453B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
FR2882366B1 (en) 2005-02-18 2008-04-18 Coletica Sa RETICULATED CARBOHYDRATE POLYMER, IN PARTICULAR BASED ON POLYSACCHARIDES AND / OR POLYOLS
FR2889530B1 (en) 2005-08-05 2008-02-01 Rhodia Chimie Sa PRODUCT FROM GUAR PROTEIN EXTRACT, PROCESS FOR PREPARATION AND USES
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
JP5630998B2 (en) * 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー Polymers for functional particles
MX2008015195A (en) 2006-06-01 2009-01-26 Univ Duke Delivery method.
US20090117549A1 (en) 2006-07-18 2009-05-07 Weihong Tan Aptamer-based methods for identifying cellular biomarkers
US9662824B2 (en) 2006-08-15 2017-05-30 Ecosynthetix Ltd. Process for producing biopolymer nanoparticles
US20080138408A1 (en) 2006-11-13 2008-06-12 Siddharth Venkatesh Drug delivery system and method
FI20065800A0 (en) 2006-12-13 2006-12-13 Glykos Finland Oy Polyvalent bioconjugates
US8481717B2 (en) 2007-02-22 2013-07-09 Corn Products Development Inc. Crosslinking reactions
US20110038939A1 (en) 2007-07-16 2011-02-17 Northeastern University Therapeutic stable nanoparticles
ES2647538T3 (en) 2007-09-28 2017-12-22 Pfizer Inc. Addressing to cancer cells using nanoparticles
US9186317B2 (en) 2007-11-26 2015-11-17 Stc.Unm Active nanoparticles and method of using
US8563066B2 (en) 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
WO2009146147A2 (en) 2008-04-05 2009-12-03 University Of Florida Research Foundation, Inc. Target-responsive hydrogels
US20090312402A1 (en) 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
JP2012505243A (en) * 2008-10-09 2012-03-01 ノースイースタン・ユニバーシティ Multifunctional self-assembled polymer nanosystem
EP2360188B1 (en) * 2008-11-05 2014-09-17 National University Corporation Tokyo Medical and Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
CN102300908B (en) 2008-12-03 2014-12-17 生态合成材料有限公司 Process for producing biopolymer nanoparticle biolatex compositions having enhanced performance and compositions based thereon
EP2196196A1 (en) 2008-12-10 2010-06-16 Medipol S.A. Compound, medicament, vaccine composition and nanocapsules
WO2010084088A2 (en) * 2009-01-21 2010-07-29 Basf Se Starch nanoparticles for drug delivery systems
WO2010091300A1 (en) 2009-02-06 2010-08-12 Nerites Corporation Bioadhesive constructs with polymer blends
US20110014296A1 (en) 2009-07-17 2011-01-20 National Chiao Tung University Drug Delivery Nanodevice, its Preparation Method and Uses Thereof
EP2509445B1 (en) 2009-12-10 2019-01-23 Dow Global Technologies LLC Process for preparing stable starch dispersions
AU2011264699B2 (en) 2010-06-07 2016-06-30 Dow Global Technologies Llc Process for preparing stable dispersions of starch particles
WO2012075414A2 (en) 2010-12-02 2012-06-07 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
US9197380B2 (en) * 2010-12-17 2015-11-24 Cisco Technology, Inc. Repeater nodes in shared media networks
US20120309246A1 (en) 2011-06-03 2012-12-06 Alexander Tseitlin Curable biopolymer nanoparticle latex binder for mineral, natural organic, or synthetic fiber products and non-woven mats
CA2790763A1 (en) 2012-05-31 2013-11-30 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
CN113876600B (en) 2015-10-21 2024-05-17 密歇根大学董事会 Detection and treatment of caries and microcavities with nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20100166872A1 (en) * 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20090196831A1 (en) * 2006-05-04 2009-08-06 Emory University Nanostructures, methods of synthesizing thereof, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERR ET AL.: "Aptamer-Conjugated Nanopartides for Selective Collection and Detection of Cancer Cells", ANAL. CHEM., vol. 78, 2006, pages 2918 - 2924, XP003023245 *

Also Published As

Publication number Publication date
US20130337065A1 (en) 2013-12-19
CA2819240A1 (en) 2012-06-07
EP2645991A2 (en) 2013-10-09
US20210338585A1 (en) 2021-11-04
EP2645991A4 (en) 2017-04-05
US20150025029A1 (en) 2015-01-22
US11369570B2 (en) 2022-06-28
US20130090467A1 (en) 2013-04-11
US20120141551A1 (en) 2012-06-07
CA2819240C (en) 2021-06-15
AU2011336352B2 (en) 2015-05-28
JP2014505672A (en) 2014-03-06
US10285943B2 (en) 2019-05-14
AU2011336352A1 (en) 2013-05-02
JP6035633B2 (en) 2016-11-30
US20190374469A1 (en) 2019-12-12
WO2012075414A2 (en) 2012-06-07
EP2645991B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
CA2819240C (en) Aptamer bioconjugate drug delivery device
Shin et al. Tannic acid as a degradable mucoadhesive compound
Mukhopadhyay et al. pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery
Liu et al. Galactosylated chitosan-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
JP2015520197A5 (en)
Anirudhan et al. Nanoparticle assisted solvent selective transdermal combination therapy of curcumin and 5-flurouracil for efficient cancer treatment
WO2010091192A3 (en) Nanoscale platinum compounds and methods of use thereof
WO2013135359A8 (en) Targeting aminoacid lipids
WO2011084620A3 (en) Particles for multiple agent delivery
WO2006010083A3 (en) Biodegradable nanoparticles
WO2010131907A3 (en) Sirna delivery system using self-assembled polymeric nanoparticles
WO2014014613A3 (en) Self-assembling peptides, peptide nanostructures and uses thereof
MY171929A (en) Corticosteroids for the treatment of joint pain
WO2010014913A8 (en) Toll-like receptor agonist formulations and their use
Di Martino et al. Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles
WO2010064252A3 (en) Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
Koshani et al. Natural emulgel from dialdehyde cellulose for lipophilic drug delivery
WO2008022146A3 (en) Polymer-surfactant nanoparticles for sustained release of compounds
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
WO2007131193A3 (en) Main chain acid-degradable polymers for the delivery of bioactive materials
WO2011088456A3 (en) Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
WO2011088178A3 (en) Personal care composition comprising a hydrophobically modified cationic polysaccharide
WO2012092486A3 (en) Modified release benzimidazole formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11845209

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011336352

Country of ref document: AU

Date of ref document: 20111202

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2819240

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013542213

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13990278

Country of ref document: US